医药中间体是指在药物合成过程中作为关键步骤的反应产物或原料物质,它们通常是化学结构较为简单的化合物,通过一系列化学反应可以转化为最终的药物成品。这些中间体在制药工业中扮演着重要角色,是实现复杂药物分子合成的关键组成部分。
特点医药中间体的研发和生产是一个复杂的过程,通常包括以下几个步骤:
随着化学合成技术的进步和新技术的应用(如绿色化学、计算机辅助设计等),医药中间体的研发与生产正朝着更加高效、环保的方向发展。同时,对药物分子结构的深入理解也为开发更有效的治疗方案提供了更多可能性。
| 中文名称 | 英文名称 | CAS号 | 化学式 |
|---|---|---|---|
| 氨基吡嗪 | 2-Aminopyrazine | 5049-61-6 | C4H5N3 |
| 氨基十二聚乙二醇羟基 | amino-PEG12-alcohol | 1345681-71-1 | C24H51NO12 |
| 氨基-PEG3-羧酸 | 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoic acid | 784105-33-5 | C9H19NO5 |
| 氨噻肟酸 | cefotaxime | 65872-41-5 | C6H7N3O3S |
| 氧杂环丁烷-3-甲醇 | oxetan-3-ylmethanol | 6246-06-6 | C4H8O2 |
| 氧杂环丁烷-3-基甲磺酸酯 | oxetan-3-yl methanesulfonate | 148430-81-3 | C4H8O4S |
| 氧头孢母核 | (6R,7R)-benzhydryl 7-(4-methylbenzamido)-3-(chloromethyl)-8-oxo-5-oxa-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate | 91177-27-4 | C29H25ClN2O5 |
| 氧唑沙星杂质4 | Ethyl 3-(cyclopropylamino)-2-(2,4-dichloro-3-methylbenzoyl)acrylate | 103877-38-9 | C16H17Cl2NO3 |
| 氧哌嗪酸 | (R)-<<(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl>amino>(4-hydroxyphenyl)acetic acid | 62893-24-7 | C15H17N3O6 |
| 氧化白藜芦醇-3'-O-Beta-D-吡喃葡萄糖苷 | oxyresveratrol 3'-O-β-D-glucopyranoside | 144525-40-6 | C20H22O9 |
| 氧化毒扁豆碱 | (+/-)-eseroline | 469-22-7 | C13H18N2O |
| 氧代-(4-三氟甲基-苯基-乙氰 | 4-(trifluoromethyl)benzoyl cyanide | 80277-40-3 | C9H4F3NO |
| 氢鲲盐酸盐 | hydroquinidine hydrochloride | 1476-98-8 | C20H26N2O2*ClH |
| 氢溴酸里丹 | Ridane Hydrobromide | 64543-93-7 | C9H18BrNO2 |
| 氢氧化镱 | Ytterbium hydroxide (Yb(OH)3) | 16469-20-8 | H3O3Yb |
| 氟非尼酮杂质2 | 1-(3-Fluorophenyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid | 1107650-68-9 | C12H8FNO3 |
| 氟维司群-9-砜 | ICI 182,780 | 98008-06-1 | C32H47F5O4S |
| 氟甲基2-吡啶基砜 | 2-((fluoromethyl)sulfonyl)pyridine | 1365765-53-2 | C6H6FNO2S |
| 氟氯化胆碱 | fluoromethylcholine chloride | 459424-38-5 | C5H13FNO*Cl |
| 氟替卡松丙酸酯中间体 | 17-propionate carbothioic acid | 80474-45-9 | C24H30F2O5S |
| 氟哒嗪草酯 | flufenpyr-ethyl | 188489-07-8 | C16H13ClF4N2O4 |
| 氟化氢吡啶 | pyridine hydrogenfluoride | 32001-55-1 | C5H6N*F |
| 氟乙醛 | 2-fluoroacetaldehyde | 1544-46-3 | C2H3FO |
| 氘代喹啉 | quinoline-d7 | 34071-94-8 | C9H7N |
| 氘代二苯并噻吩 | dibenzothiophene-d8 | 33262-29-2 | C12H8S |
| 比马酰胺 | 17-phenyl-trinor-PGF2alpha amide | 155205-89-3 | C23H33NO4 |
| 正丙基乙烯基醚 | vinyl propyl ether | 764-47-6 | C5H10O |
| 次氯血红素 | Deuteroferriheme | 21007-21-6 | C30H28ClFeN4O4 |
| 樟脑磺酸氯吡格雷 | clopidogrel (1R)-(-)-camphor-10-sulfonate | 120202-68-8 | C10H16O4S*C16H16ClNO2S |
| 樟脑吡酰胺 | Camphotamide | 4876-45-3 | C21H32N2O5S |
| 棘白菌素B | Echinocandin B, 1-[(4R,5R)-4,5-dihydroxy-L-ornithine]- | 79411-15-7 | C34H51N7O15 |
| 格列嘧啶 | glymidine | 339-44-6 | C13H15N3O4S |
| 栎精-3-O-Β-D-吡喃葡萄糖基-6’’-乙酸盐 | quercetin 3-O-(6''-O-acetyl)-β-D-glucopyranoside | 54542-51-7 | C23H22O13 |
| 柳氮磺胺吡啶杂质G(EP) | 5-(2-(4',5-Bis(pyridin-2-ylsulfamoyl)biphenyl-2-yl)diazenyl)-2-hydroxybenzoic acid | 1391062-37-5 | C29H22N6O7S2 |
| 柳氮磺嘧啶 | Salazosulfadimidine | 2315-08-4 | C19H17N5O5S |
| 柳氮磺吡啶3-异构体 | Sulfasalazine 3-Isomer | 66364-71-4 | C18H14N4O5S |
| 柠檬酸胆碱 | (3R)-3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxyethyl(trimethyl)azanium | 77-91-8 | C11H21NO8 |
| 柠檬酸噻嘧啶 | pyrantel citrate | 5685-86-9 | C6H8O7*C11H14N2S |
| 枸橼酸托烷司琼 | Tropisetron Citrate | 1251773-00-8 | C23H28N2O9 |
| 枸橼酸托法替尼 | Tofacitinib citrate | 540737-29-9 | C6H8O7*C16H20N6O |
| 松脂醇-4-O-beta-D-吡喃葡萄糖苷 | (+/-)-Pinoresinol-4'-O-β-D-monoglucoside | 24404-49-7 | C26H32O11 |
| 松脂醇 beta-D-吡喃葡萄糖苷 | pinoresinol-4'-O-β-D-glucopyranoside | 24404-49-7 | C26H32O11 |
| 来那替尼吡啶氮氧杂质 | Neratinib pyridine N-oxide | 1376619-94-1 | C30H29ClN6O4 |
| 杀草敏-甲基-脱苯基 | 5-amino-4-chloro-2-methyl-3(2H)-pyradizone | 17254-80-7 | C5H6ClN3O |
| 木质素 | lignin | 8068-03-9 | C81H92O28 |
| 月桂醇磺基乙酸酯钠盐 | 7-(S-methylsulfonimidoyl)-5-(n-hexyl)-xanthone-2-carboxylic acid | 58761-87-8 | C21H23NO5S |
| 月桂酰-L-肉碱 | dodecanoylcarnitine | 25518-54-1 | C19H37NO4 |
| 替诺福韦二磷酸酯 | Tenofovir diphosphate | 166403-66-3 | C9H16N5O10P3 |
| 替来他明中间体2 | (1-Bromocyclopentyl)-2-thienyl ketone | 94139-04-5 | C10H11BrOS |
| 曲非奈肽 | trofinetide | 853400-76-7 | C13H21N3O6 |